Idiopathic intracranial hypertension in males

Discussion

The IIH typically occurs in overweight women between the ages of 15-40 years; it rarely occurs in men.2 An epidemiological study conducted in the United States estimated that women are 8 times likely to be affected by IIH than men, with an annual incidence of 0.3/100,000 in men aged 15-44 years old, as compared to women of the same age (3.5/100,000).6 However, the incidence of IIH probably differs from region to region due to variations in the prevalence of obesity in each region. In a study preformed in a Middle Eastern country (Oman), the estimated annual incidence was 2.18/100,000 in the general population with women being 3 times more likely to be affected than men.7 The typical presentation of IIH includes signs and symptoms of increased ICP.5 Furthermore, IIH can uncommonly present with a fulminant presentation, which is defined as an acute presentation featuring severe vision loss that occurs over the course of several days.8

Although the clinical manifestations of IIH in men were reported to be similar to those in women, men were more likely to present with severe visual acuity and visual field defects when compared with women.2,4 Furthermore, Bruce3 and his colleagues reported that men tend to experience a shorter amount of time between the onset of the first symptom to the time of diagnosis when compared to women; however, this could be attributed to the more severe vision loss experienced by men at the time of presentation. Interestingly, it was reported that men are more likely than women to require surgical intervention for visual impairment.2 PubMed was searched using the following search terms: “Pseudotumor cerebri”, “Idiopathic intracranial hypertension”, “Men”, “Man”, “Male”, and “Males”. Relevant manuscripts were retrieved and the results were used to provide an overview of the extant literature. We found 47 males with IIH reported in the literature.2,4

A diagnosis of IIH is made with the aim of excluding any intracranial pathology. The modified Dandy diagnostic criteria were applied to our patient, as modern imaging techniques (such as MRI or CT) were used to exclude space-occupying lesions and ventricular enlargement. Additionally, MRI venography or CT venogram must be performed to exclude venous sinus thrombosis.5 An increased opening pressure without any CSF abnormalities is the typical diagnostic picture of IIH.5

The aim of treatment for patients with IIH is to preserve their vision and to reduce increased ICP.1 Weight loss can decrease the symptoms associated with IIH; however, with visual field deficits, weight loss alone is insufficient for decreasing ICP within the appropriate time frame.1 Of the 47 male patients who were reported in the literature, only one patient was treated with weight loss alone and showed no improvement.2

Patients without vision loss are usually treated with a carbonic anhydrase inhibitor, such as acetazolamide, as a first-line treatment to decrease increased ICP. Most patients typically respond to doses of 1–2 g, and higher doses of up to 4 g may be used, but some patients cannot tolerate the side effects.1 If the patient cannot tolerate acetazolamide, an alternative anhydrase inhibitor (such as methazolamide or furosemide) or other diuretics can be used. In our patient, described above, the maximum dose of acetazolamide given was 2 g per day over 2 days. However, due to the rapidly progressive visual deterioration of our patient, we decided to treat him surgically. Of the 47 patients examined herein, 24 of them were treated with acetazolamide without surgical intervention; of these, 17 presented with headache (64.7% of those patients improved with medical treatment) and 12 presented with visual symptoms (66.7% of those patients responded to medical treatment). However, in patients with acute visual field loss, or those who responded poorly to medical treatment, emergency surgical intervention should be considered. Surgery in the form of optic nerve sheath fenestration (ONSF) or shunting is indicated when patients have significant vision loss on presentation, which is refractory to maximum medical treatment.9 In patients who predominantly present with vision loss that is refractory to medical therapy, ONSF is usually preferred. On the other hand, for those patients who predominantly present with headache and who have failed to respond to medical therapy, CSF diversion is the preferred option.9 Of our 47 patients, 10 of them were treated surgically (7 with ONSF, 2 with lumbar–peritoneal shunts, and one who had both an ONSF/lumbar–peritoneal shunt); 60% of those 10 patients showed some improvement following surgical treatment.

It has been suggested that men tend to have more severe visual outcomes when compared to women.2,4 Interestingly, a recent randomized placebo-controlled trial of acetazolamide reported a significant association between male gender and medical treatment failure.10 The study was conducted to predict the risk factors that were associated with progressive vision loss in patients with IIH; these factors included low-sodium and weight-reduction diets. Patients in the trials were randomly allocated to receive either acetazolamide or placebo, and they were then followed for 6 months. Of all participants (147 females and 4 males), 7 patients (2 of which were men) met the criteria for treatment failure, with an odds ratio of 26.21 (95% confidence interval [CI]: 1.61-433.00; p=0.02) for males compared to females.10 Our report supports the role of early surgical intervention in men with severe vision loss. However, due to the limited reported cases, which were treated surgically, further studies are necessary to support early surgical intervention in this group of patients. Additionally, to our knowledge, the exact time between vision deterioration and the time at which vision can be aggressively preserved is not known.

In conclusion, although IIH is less common in men than in women, men are more likely to develop vision loss, which is typically severe and less likely to respond to medical treatment. Surgical intervention might be considered early in the treatment of men with rapidly progressive visual loss. Further prospective studies are needed to evaluate the role of early surgical intervention in comparison to medical treatment in this group of patients.